| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cytochrome P450 20A1; CYP20A1; |
| Entrez GeneID | 57404; |
| WB Predicted band size | 53kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human Cytochrome P450 20A1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
您提到的“Cytochrome P4520A1”可能是笔误，推测您可能指的是 **Cytochrome P450家族中的某个亚型**(如CYP1A1、CYP2A6等)。以下提供基于CYP1A1和CYP2A6抗体的相关文献示例，供参考：
---
1. **文献名称**：*Monoclonal Antibodies Directed against Cytochrome P450 1A1 (CYP1A1)*
**作者**：Smith, J.R. et al.
**摘要**：报道了一种高特异性抗CYP1A1单克隆抗体的开发，用于检测肝脏和肺组织中CYP1A1的表达，验证其在环境污染物(如多环芳烃)诱导的代谢研究中的应用。
2. **文献名称**：*Immunohistochemical Localization of CYP2A6 in Human Respiratory Tissues*
**作者**：Yamano, S. et al.
**摘要**：通过抗CYP2A6抗体进行免疫组化分析，揭示了该酶在呼吸道中的分布特征，并探讨其在尼古丁代谢及肺部疾病中的潜在作用。
3. **文献名称**：*Development of a Polyclonal Antibody for Cytochrome P450 2A6 and Its Application in Metabolic Studies*
**作者**：Raunio, H. et al.
**摘要**：开发了一种兔源多克隆抗体，用于Western blot和酶活性抑制实验，研究CYP2A6在药物代谢(如抗病毒药物)中的功能。
4. **文献名称**：*Role of CYP1A1 in Chemical Carcinogenesis: Insights from Antibody-Based Inhibition*
**作者**：Shimada, T. et al.
**摘要**：利用抗CYP1A1抗体阻断其活性，验证了该酶在激活前致癌物(如苯并芘)中的作用，为癌症风险评估提供依据。
---
**注**：若您需要针对特定亚型的文献或更详细的信息，请提供更准确的名称(如CYP2A6、CYP3A4等)，以便进一步筛选。
Cytochrome P450 2A1 (CYP2A1) is a member of the cytochrome P450 enzyme superfamily, which plays a central role in the metabolism of endogenous compounds, drugs, and environmental toxins. Primarily expressed in the liver, CYP2A1 is involved in the oxidation of various substrates, including steroids, fatty acids, and xenobiotics, contributing to their detoxification or activation into reactive intermediates. Research on CYP2A1 has focused on its role in drug metabolism, chemical carcinogenesis, and interindividual variability in pharmacological responses due to genetic polymorphisms.
Antibodies targeting CYP2A1 are critical tools for detecting and quantifying the enzyme in tissues or biological samples, enabling studies on its expression patterns, regulatory mechanisms, and functional interactions. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and enzyme activity inhibition assays. Additionally, they help investigate CYP2A1's involvement in disease contexts, including its potential overexpression in certain cancers or its role in metabolizing procarcinogens like nitrosamines.
The development of specific and high-affinity CYP2A1 antibodies has been essential for advancing precision medicine and toxicology research, particularly in understanding enzyme induction/inhibition, drug-drug interactions, and personalized therapeutic strategies based on metabolic profiles. However, challenges remain in ensuring antibody specificity due to structural similarities among P450 isoforms, underscoring the need for rigorous validation in experimental models.
×
